Genetic polymorphisms at miRNA-binding sites may affect miRNA-mediated gene regulation. Thus, miRNA-binding site polymorphisms in double-strand break (DSB) repair genes may affect DNA repair capacity, which in turn could affect cancer prognosis. To determine whether miRNA-binding site polymorphisms in DSB repair genes are associated with the risk of recurrence of squamous cell carcinoma of the non-oropharynx (SCCNOP), we used a log-rank test and multivariable Cox models to evaluate the associations between miRNA-binding site polymorphisms in DSB repair genes and SCCNOP recurrence. Compared with patients without common homozygous genotypes, patients with the variant genotypes of ATM rs227091, LIG3 rs4796030, and RAD51 rs7180135 had significantly better disease-free survival (DFS) (log-rank P = 0.046, 0.002, and 0.041, respectively) and lower risk of disease recurrence [HR (95% CI) = 0.7 (0.6-0.9), 0.6 (0.5-0.9), and 0.7 (0.6-0.9), respectively]. Furthermore, patients with the variant genotypes of these 3 polymorphisms had significantly lower recurrence risk than those without common homozygous genotypes did [HR = 0.3 (95% CI = 0.2-0.7)]. Among patients who received chemoradiation, those with the individual or combined variant genotypes of the three polymorphisms had a significantly lower risk of disease recurrence than those with the individual or combined common homozygous genotypes did. The individual or combined variant genotypes of the ATM rs227091, LIG3 rs4796030, and RAD51 rs7180135 polymorphisms significantly modify the risk of SCCNOP recurrence, particularly for patients treated with chemoradiation. Future prospective studies with larger sample sizes are warranted to validate these findings to enable more effective personalized treatment for SCCNOP patients.
Introduction
Squamous cell carcinoma of head and neck (SCCHN) is the sixth most common cancer worldwide. In the USA, approximately 60 000 new cases of SCCHN were reported and 12 000 peopled died from the disease in 2015 (1, 2) . One SCCHN subtype is squamous cell carcinoma of the non-oropharynx (SCCNOP), which arises mainly in the oral cavity, hypo-oropharynx, and larynx (3) . Although advances in diagnostic and therapeutic approaches for SCCNOP have been made in past several decades, the disease's high rate of recurrence remains a main cause of mortality among SCCNOP patients (4, 5) . The incidence of SCCNOP recurrence varies among patients, even among those who have similar disease stages at diagnosis or who receive the same treatments, which implies that other factors, such as genetic factors, contribute to SCCNOP recurrence.
Various endogenous and exogenous stimuli (e.g. ionizing radiation, tobacco and alcohol, reactive oxygen species, genotoxic drugs) contribute to DNA damage. The DNA damage repair (DDR) response activates specific DNA damage signaling, cell cycle regulation, and apoptosis to maintain genomic integrity (6, 7) . The DNA repair system consists of base excision repair (BER), nucleotide excision repair, and double-strand break (DSB) repair (8) . DSB repair plays a central role in fixing the DNA damage caused by cancer treatments, including radiotherapy and chemotherapy. DNA repair capacity may significantly influence the efficacy of these treatments (9) .
Increased evidence has suggested that miRNAs take actively part in the regulation of the DNA damage/repair network (10). MicroRNAs (miRNAs) are small non-coding RNAs that can modulate gene expression and the translation of their target messenger RNAs (11) . Because they can regulate gene expression through complete or partial base pairing with target mRNAs at the 3′-untranslated region (3′UTR), resulting in mRNA cleavage or translational suppression, single-nucleotide polymorphisms (SNPs) in the predicted microRNA target sites of DNA repair genes may affect the expression of these genes and DNA repair capacity (12, 13) .
Recent studies have shown that the polymorphisms in the predicted miRNA target sites of DNA repair genes can affect the risk and clinical outcomes of patients with different types of cancer (14) (15) (16) . In previous studies, we investigated the association between variants in the miRNA target sites of DSB repair genes and SCCHN risk and between selected polymorphisms in nucleotide excision repair core genes and risk of squamous cell carcinoma of the oropharynx recurrence (17, 18) . However, the roles that genetic variants in the miRNA-binding sites of DSB repair genes have in modulating the risk of SCCNOP recurrence remain unclear. Thus, the purpose of this study was to determine the extent to which miRNA-binding site polymorphisms in DSB repair pathway genes are associated with risk of SCCNOP recurrence.
Materials and methods

Patients
A total of 1016 patients with newly diagnosed, previously untreated, histologically confirmed index SCCNOP were included in this study. The details of the patients' enrollment were described previously (19) . Briefly, the patients were recruited irrespective of their age, sex, ethnicity, or clinical disease stage. All patients provided written informed consent before enrollment and the study protocol was approved by the Institutional Review Board of The University of Texas MD Anderson Cancer Center. All patients were interviewed to collect the relevant information on demographic, epidemiologic, and clinical characteristics as well as blood samples for genetic testing at the time of initial presentation to our institution.
The patients were monitored and followed through their treatment and post-treatment course by regular clinical and radiographic examinations. Patients typically had either routine serial imaging or follow-up imaging on the basis of symptoms or findings on physical examination. Patients were considered to be disease-free if no disease was documented on the date of their last visit with the head and neck surgeon, head and neck radiation oncologist, or head and neck medical oncologist. Patients were considered to have experienced disease recurrence if they had appearance of a new lesion of the same histologic subtype as the original lesion verified by biopsy (incisional, excisional, or needle biopsy), reappearance of any lesion that had disappeared, or development of tumorrelated symptoms. Strict criteria which were used to distinguish distant recurrence, regional recurrence, local recurrence, and second primary tumors were described previously (19) . Clinical data, including the stage of the index tumor, site of the index tumor, and treatment, were obtained at initial presentation and through follow-up examinations. Index cancer stage was dichotomized into early stage (clinical stage I and II) and late stage (clinical stage III and IV). Treatment was dichotomized as treatment with DNA-damaging agents (surgery with radiation and/or chemotherapy) and treatment without such agents (surgery only). All patients also provided epidemiologic data, including alcohol use and smoking status, at presentation.
Selection and genotyping of SNPs
Several SNPs within miRNA-binding sites in the 3′UTR of the DSB repair pathway were selected using methods for identifying putative miRNAbinding sites and were evaluated in several types of cancer as described previously (14, 17) . Genomic DNA was extracted from the buffy coat of whole blood samples obtained before treatment using the Qiagen DNA Blood Mini Kit (Qiagen) per the manufacturer's instructions. These DNA samples were subjected to genotyping with TaqMan techniques to identify potentially functional SNPs. For quality control, the genotyping was repeated on 10% of the samples at random and a 100% concordance between duplicates was obtained. SNPs with a minor allele frequency of ≥10% in our SCCOP patient population were included in the final analysis.
Statistical analysis
Differences in mean age and follow-up time between patients with and without recurrence were assessed using the Student t-test. The chi-squared test was used to evaluate the differences in ethnicity, sex, smoking status, alcohol use, tumor stage, comorbidity, treatment, genotype distributions, and allele frequencies between patients with and without recurrence. The log-rank test was used to assess differences in DFS between the groups. Univariate Cox proportional hazards regression models were used initially to assess the associations between individual epidemiologic risk factors, clinical characteristics (including stage, comorbidity, and treatment variables), and time to recurrence. The data were consistent with the assumption of the Cox proportional hazards regression model according to an examination of Kaplan-Meier survival curves and log-minus-log survival plots. Associations between miRNA-binding site polymorphisms in DNA repair genes and risk of recurrence were quantified by calculating hazard ratios (HRs) and their 95% confidence intervals (CIs) with adjustment for potential confounders, including age, sex, ethnicity, smoking, alcohol use, tumor stage, comorbidity, and treatment. For all analyses, statistical significance was set at P < 0.05 and all tests were two-sided. The SAS software program (version 9.4; SAS Institute) was used for all statistical analyses. 
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Results
The 1016 patients with incident SCCNOP were followed from May 1995 to October 2013. The median follow-up time was 44.7 months (range: 0.8-170.9 months). During follow-up, 247 patients had disease recurrence. The characteristics and 5-year recurrence rates of all patients and patients who had disease recurrence are presented in Table 1 . The DFS differences were significant different between the groups regarding to sex, smoking, disease stage, and treatment, while such significant differences were not observed among other groups. The genotype distributions of miRNA-related SNPs, the 5-year recurrence rates, and the associations between the SNPs and recurrence risk based on univariate and multivariable analyses are shown in Table 2 . Patients with the ATM rs227091 TC/ CC, LIG3 rs4796030 CA/AA, and RAD51 rs7180135 AG/GG variant genotypes had significantly better DFS than patients with the corresponding common homozygous genotypes did (log-rank P = 0.046, 0.002, and 0.041, respectively) ( Figure 1 ). After adjustment for potential cofounders, including age, sex, ethnicity, smoking status, alcohol use status, disease stage, comorbidity, and treatment, the multivariable analysis showed that patients with the ATM rs227091 TC/CC, LIG3 rs4796030 CA/AA, and RAD51 rs7180135 AG/GG genotypes had a significantly smaller risk of disease recurrence than patients with the corresponding common homozygous genotypes did [aHR (95% CI) = 0.7 (0.6-0.9), 0.6 (0.5-0.9), and 0.7 (0.6-0.9), respectively]. An analysis of the patients divided into different groups based on the numbers of the variant genotypes of the three significant polymorphisms revealed that patients with at least one gene variant of the three polymorphisms had significantly better DFS (log-rank P < 0.001) ( Figure 2 ) and an even lower risk of disease recurrence than patients without the corresponding variant genotypes did [aHR = 0.3 (95% CI = 0.2-0.7)] (Table 3) .
We further evaluated the associations between individual and combined variant genotypes of the three significant miRNA binding-site polymorphisms and risk of SCCNOP recurrence in patients stratified by treatment. Among the patients treated with radiation and/or chemotherapy with or without surgery, those carrying the ATM rs227091, LIG3 rs4796030, RAD51 rs7180135, or combined variants genotype had a significantly smaller risk of disease recurrence than patients carrying the corresponding common homozygous genotypes did [aHR (95% CI) = 0.7 (0.6-0.9), 0.6 (0.5-1.0), 0.7 (0.5-0.9), and 0.4 (0.2-0.9), respectively] ( Table 4 ). In contrast, among the patients treated with surgery only, only those carrying the combined variant genotypes had a significantly smaller risk of disease recurrence [aHR = 0.6 (95% CI = 0.4-0.8)].
Discussion
In this study, we evaluated the associations between miRNAbinding site polymorphisms in DSB repair pathway genes and disease recurrence in SCCNOP patients. We found that the variant genotypes of LIG3 rs4796030, ATM rs227091, and RAD51 rs7180135, or a combination of these genotypes, were significantly associated with a reduced risk of disease recurrence, particularly among patients who received chemoradiation. Once associations between these polymorphisms and the risk of SCCNOP recurrence are confirmed, clinicians could use these functional polymorphisms as biomarkers to identify patients with a low risk of recurrence for optional treatment to achieve better survival and improved quality of life.
ATM plays a critical role in the recognition, signaling, and repairing of DSBs caused by chemoradiation. Previous studies have investigated associations between ATM SNPs and survival following cancer treatment (20, 21) . However, those studies did not report on the association between miRNA-binding site polymorphisms in DSB repair pathway genes and disease a P values are the products of log-rank tests for differences in disease-free survival between the two groups.
recurrence in SCCNOP patients. One report on the miRNA-mediated downregulation of ATM showed that levels of miR-421, which targets the 3′UTR of ATM mRNA, were enhanced 6-fold in post-transcriptional regulation. In head and neck tumors, the miRNA-mediated downregulation of ATM increases tumor radiosensitivity (22) . Another microarray study in which 27 miRNAs showed differential alteration in response to radiation in an ATM-dependent manner identified a miRNA signature that could predict radiosensitivity in HNSCC patients. Such results were validated by analyzing available HNSCC samples in The Cancer Genome Atlas database (23) . In the present study, we found that the ATM rs227091 genotype conveyed a significantly reduced risk of disease recurrence. Therefore, we postulate that this genetic variant in the 3′-UTR of ATM alters miRNA regulation, thereby leading to loss of ATM function. Thus, future studies in this area should focus on identifying the corresponding miRNAs that potentially control these 3′-UTR variations. Such miRNAs may serve as therapeutic targets in SCCNOP patients.
In various tumor types, RAD51 overexpression is associated with a more aggressive cancer phenotype and treatment resistance, whereas RAD51 downregulation reduces DNA damage repair ability and increases sensitivity to chemotherapy and radiotherapy (24, 25) . Teo et al. confirmed that RAD51 rs7180135 has a potentially protective role in bladder cancer and that the RAD51 rs7180135 variant allele is associated with improved cancer-specific survival (14) . The authors predicted that miR-197 binds more strongly to the G allele and that the binding reduces RAD51 expression (14) . Several studies have shown differential expression of miR-197 among cancer types, with upregulated miR-197 expression in squamous cell carcinoma of the tongue and in male breast cancer and downregulated miR-197 expression in gastric cancer (26) (27) (28) . On the basis of these studies' results, we speculate that the RAD51 rs7180135 polymorphism elicits functional changes that affect tumor radiosensitivity and thus treatment outcome. MiR-197 or other miRNAs may regulate RAD51 through miR197-mRNA binding. Before these miRNAs can serve as therapeutic targets and/or prognostic markers of clinical outcome in SCCNOP patients, however, additional studies are needed to verify our hypothesis that functional changes elicited by RAD51 rs7180135 polymorphism are modulated by miR-197 or other miRNAs.
Our results suggest that the Lig3 rs4796030 polymorphism has a significant effect on the risk of SCCNOP recurrence. Lig3, initially considered to be a BER protein, also interacts with PARP1 and XRCC1 to exert its role in the alternative nonhomologous end joining DSB repair pathway (29) . DNA lesions that result from stimuli by tobacco or alcohol-two major risk factors for SCCNOP-are repaired mainly through the BER pathway (30) . In contrast, ATM and RAD51 play key roles in repairing DSBs caused mainly by chemoradiation and the exact roles of Lig3 in DSB repair pathways, particularly in the alternative nonhomologous end joining pathway (29, 31) , remain unclear. To date, no studies have investigated the association between LIG3 rs4796030 and risk of cancer recurrence. One previous study showed that LIG3 can be modulated as a downstream target by c-MYC through the negative regulation of miR-150 and miR-22 and ultimately contributes to increased error-prone repair (32) . On the basis of current data, we cannot conclude whether the LIG3 rs4796030 genotype interacts directly with miRNAs, including miR-150 and miR-22. Thus, further validation of our findings regarding the association of LIG3 rs4796030 with recurrence risk is required.
Compared with patients who have human papillomavirusrelated squamous cell carcinoma of oropharynx, which is more sensitive to radiotherapy, most SCCNOP patients have human papillomavirus-negative tumors and are more likely to have somatic mutations, such as p53 mutations. Such mutations may contribute to poor response to cancer treatment, thereby altering the risk of disease recurrence. In our study, patients with the ATM rs227091 TC/CC, LIG3 rs4796030 CA/AA, and RAD51 rs7180135 AG/GG variant genotypes had significantly better DFS and a smaller recurrence risk than patients with the corresponding common homozygous genotypes. It is biologically likely that these three genetic variants, owing to their interaction with the corresponding miRNA in 3′-UTR miRNA-binding sites, alter the expression of these three genes and lead to interindividual differences in DNA repair capacity phenotypes. This in turn may result in different susceptibility to the genotoxic effects of chemoradiation and thus different clinical outcomes. However, these hypotheses need to be tested in future studies. Overall, the functional significance of these nine variants in the DSB repair pathway is still largely uncertain. Although we did not identify a significant association of some of these putatively functional SNPs with risk of recurrence, it becomes obvious that the results could vary depending on many factors for the nominal statistical significance, particularly for weak associations of individual SNPs such as the results we found in the current study.
The lack of significance for other SNPs could be because (i) the expression level or biological function of certain genes could only be determinant for the entire DNA repair process they are belonging to the process; (ii) the SNP of study might not affect either biological function or expression level of the gene of interest; and (iii) the SNP might not affect the DNA repair function, whereas it may be in linkage disequilibrium with other known or unknown functional polymorphisms or adjacent susceptibility loci of the gene, thereby affecting this gene expression and activity. For example, The PARP1 is involved in non-homologous end joining repair pathways together with LIG3 and XRCC1 (14) . Based on differences of total ∆∆G for the miRNAs predicted to bind to LIG3 rs4796030 and PARP1 rs8679 between their variant and wild-type alleles, the variant alleles would have a reduced miRNA-mRNA binding ability and an increased LIG3 and PARP1 expression and such higher levels of DNA repair proteins would cause increased DNA repair and reduced cancer risk (14) . However, we speculate in tumors with chemoradiation, the increased DNA repair proteins may provide a favorable advantage for tumor cells to survive, leading to increased risk of cancer recurrence. Therefore, the altered PARP1 and LIG3 expression caused by LIG3 rs4796030 and PARP1 rs8679 might modify the susceptibility to chemoradiation, thus influencing risk of SCCNOP recurrence.
The significance and degree of these SNPs in this study thus needs to be further investigated in future studies with larger sample sizes. Additionally, different genetic backgrounds and patient characteristics might explain, to some extent, the somewhat negative results with respect to the impact of these DSB repair pathway SNPs. Other factors could also contribute to the negative results, including small sample size of outcome events limited the statistical power to detect a significant effect, different cancer types, variations in stage, different treatments, interactions between functional variants of these SNPs and therapeutic agents used, inclusion of different ethnic groups in a single study, and inadequate adjustment for other confounding factors as well as different genetic models used for analysis.
Although this is the first study to comprehensively investigate the role of SNPs residing in miRNA target sites of DSB repair pathway genes in association with risk of SCCNOP recurrence, our study still had several potential limitations. First, because most patients in the study were non-Hispanic whites, its results may not be generalizable to other ethnic groups. Furthermore, because of the retrospective, hospital-based nature of the parent study, a selection bias may have been present. Data on smoking duration and intensity, such as pack-year, and human papillomavirus status should be included for adjustment and similar analysis with large sample size of SCCNOP patients should be considered in our future studies. Finally, the study's small sample size and limited number of outcome events in some strata might have caused the results by chance.
In conclusion, our study showed that the genotypic variants LIG3 rs4796030, ATM rs227091, and RAD51 rs7180135, individually or in combination, significantly modify the risk of recurrence in SCCNOP patients, especially those treated with chemoradiation. However, our findings should be validated in larger studies to confirm these miRNA binding-site SNPs as potential prognostic biomarkers. Additional studies to identify the specific miRNAs for the 3′UTR binding sites are also needed, as such miRNAs may have potential as molecular targets for new cancer treatments. 
